To clarify the clarification, Omapro is for patients that fail treatment with tyrosine kinase inhibitors, including Gleevec, nilotonib and Sprycel, due to the T3151 mutation. Omapro is the only alternative to TKI's in that situation.
Omapro uses a different mechanism to TKI's.
Re risk, do you know whether omapro is more or less of a health risk than, say, Gleevec?
- Forums
- ASX - By Stock
- CXS
- latest wilsonhtm report
latest wilsonhtm report, page-8
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CXS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online